LKT Labs

Biochemicals for Life Science Research

Awaiting product image

Snake venom – Crotalus durissus terrificus

Product ID SC7056
Cas No.
Purity ≥98%
Product Unit SizeCostQuantityStock
100 mg $210.40 In stock
Bulk Quote

Quicklinks

Description

This product is a snake venom found in Crotalus durrisus terrificus including several toxins that cause myalgia, muscle weakness, and rhabdomyolysis. Crotoxin acts on N-type and P/Q-type Ca2+ channels to induce glutamate release and crotamine induces acetylcholine (ACh) and DA release. Crotoxin also potentiates activity at L-type Ca2+ channels. Gyrotoxin is a serine protease with thrombin-like activity. Together, these toxins may induce paralysis, acting as a neuromuscular junction (NMJ) blocker.

Product Info

Purity

≥98%
Appearance

Yellow Crystalline Solid

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

SC7056 MSDS PDF
Info Sheet

SC7056 Info Sheet PDF

References

Bucaretchi F, De Capitani EM, Hyslop S, et al. Compartment syndrome after South American rattlesnake (Crotalus durissus terrificus) envenomation. Clin Toxicol (Phila). 2014 Jul;52(6):639-41. PMID: 24940645.

Vargas LS, Lara MV, Gonçalves R, et al. The intrahippocampal infusion of crotamine from Crotalus durissus terrificus venom enhances memory persistence in rats. Toxicon. 2014 Jul;85:52-8. PMID: 24813333.

Lomeo Rda S, Gonçalves AP, Silva CN, et al. Crotoxin from Crotalus durissus terrificus snake venom induces the release of glutamate from cerebrocortical synaptosomes via N and P/Q calcium channels. Toxicon. 2014 Jul;85:5-16. PMID: 24751366.

Yonamine CM, Kondo MY, Nering MB, et al. Enzyme specificity and effects of gyroxin, a serine protease from the venom of the South American rattlesnake Crotalus durissus terrificus, on protease-activated receptors. Toxicon. 2014 Mar;79:64-71. PMID: 24412460.

Ribeiro Gde B, Almeida HC, Velarde DT, et al. Study of crotoxin on the induction of paralysis in extraocular muscle in animal model. Arq Bras Oftalmol. 2012 Oct;75(5):307-12. PMID: 23471322.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • M400220

    MK-2206 Dihydrochloride

    Akt inhibitor.

    ≥99%
  • S8169

    Suramin Hexasodium

    RyR agonist, SIRT, telomerase, P2Y, GPCR inhibi...

    ≥98%
  • R3197

    Rhynchophylline

    Oxyindole alkaloid found in Uncaria sinensis; h...

    ≥98%
  • V0269

    Vardenafil Dihydrochloride

    PDE5 inhibitor.

    ≥99%
  • A488240

    AMG-337

    Selective inhibitor of c-Met.

    ≥99%
  • S8344

    R,S-(±)-Sulpiride

    GHB agonist, D2/3 antagonist.

    ≥98%
  • N6272

    NPS-2143 Hydrochloride

    Ca2+-sensing receptor antagonist.

    ≥99%
  • N0262

    Naphazoline Hydrochloride

    α1-adrenergic agonist.

    ≥97%
  • N859614

    NVP-LDE225

    Smo inhibitor.

    ≥98%
  • B8112

    Budesonide

    Steroid; glucocorticoid agonist.

    ≥97%
  • L0226

    Lagochiline

    Diterpene alkaloid found in Lagochilus.

    ≥98%
  • K0652

    Kb NB 142-70

    PKD inhibitor.

    ≥98%
  • I088240

    (S,S)-ICG-001

    Wnt/β-catenin inhibitor

    ≥98%
  • P7059

    Proxymetacaine Hydrochloride

    Potential voltage-gated Na+ channel blocker.

    ≥98%
  • L1784

    Levetiracetam

    SV2A synaptic vesicle inhibitor.

    ≥99%
  • T1010

    7-Acetyl Paclitaxel

    Synthesis impurity

    ≥98%
  • G0181

    Gastrin Releasing Peptide, human

    Endogenous bombesin-like peptide, involved in f...

    ≥95%
  • C2916

    Chenodeoxycholic Acid

    Endogenous bile acid; FXR agonist.

    ≥98%
  • C084099

    CCCP

    Efflux pump inhibitor

    ≥99%
  • S0278

    Satraplatin

    Pt-based DNA cross-linker.

    ≥98%